Beyond cholesterol - Inflammatory cytokines, the key mediators in atherosclerosis

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 5, 2004, Pages 467-474

  Mangge, Harald ^a   Hubmann, Holger ^a   Pilz, Stefan ^a   Schauenstein, Konrad ^a   Renner, Wilfried ^a   März, Winfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Atherosclerosis; Immune mediated inflammation; Inflammatory biomarkers

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHOLESTEROL; COLONY STIMULATING FACTOR 1; CYTOKINE; CYTOKINE RECEPTOR; FRACTALKINE; FREE RADICAL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOCYSTEINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; RANTES; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; BACTERIAL INFECTION; CELL KINETICS; CHLAMYDIA; CIGARETTE SMOKING; DIABETES MELLITUS; EARLY DIAGNOSIS; ENDOTHELIUM INJURY; EXPERIENCE; GENETIC PREDISPOSITION; HERPES VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MACROPHAGE; MOLECULAR MECHANICS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; ARTERIOSCLEROSIS; AUTOIMMUNE DISEASES; CARDIOVASCULAR SYSTEM; CELL ADHESION MOLECULES; CHOLESTEROL; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; INFECTION; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 2942641885     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.081     Document Type: Review

References (104)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997;349:1436-42.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Libby P, Ridker PM, Maser A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
4. Stary HC, Chandler AB, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89:2462-78
5. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997;100:2680-90.
6. Cuomo S, Guarini P, Gaeta G, De Michele M, Boeri F, Dorn J, et al. Increased carotid intima-media thickness in children, adolescents, and young adults with a parental history of premature myocardial infarction. Eur Heart J 2002;23:1345-50.
7. Mangge H, Schauenstein K, Stroedter L, Griesl A, Erwa W, Borkenstein M. Low grade inflammation in juvenile obesity and type I diabetes associated with early signs of atherosclerosis. Experiment Clin Endocrinol Diabet 2004. In press.
8. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
9. Raines EW, Rosenfeld ME, Ross R. The role of macrophages. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol. 1. Philadelphia: Lippincott-Raven, 1996:539-55.
10. Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol. 2. Philadelphia: Lippincott-Raven, 1996:492-510.
11. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131-8.
12. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
13. Stary HC. The histological classification of atherosclerotic lesions in human coronary arteries. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol. 1. Philadelphia: Lippincott-Raven, 1996:463-74.
14. Han J, Hajjar DP, Tauras JM, Nicholson AC. Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. J Lipid Res 1999;40:830-8.
15. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
16. Falcone DJ, McCaffrey TA, Vergilio JA. Stimulation of macrophage urokinase expression by polyanions is protein kinase C-dependent and requires protein and RNA synthesis. J Biol Chem 1991;266:22726-32.
17. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 2:975-82.
18. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997;150:1687-99.
19. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 1992;140:301-16.
20. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-91.
21. Cybulsky MI, Hegele RA. The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J Clin Invest 2003;111:1118-20.
22. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001;103:1772-7.
23. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003;107:1009-16.
24. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.
25. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997;96:3264-5.
26. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
27. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
28. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990;11:97-101.
29. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995;92:3893-7.
30. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 2002;4:233-7.
31. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998;18:1972-82.
32. Stopeck AT, Nicholson AC, Mancini FP, Hajjar DP. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993; 268:17489-94.
33. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells: molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975-8.
34. Gierens H, Nauck M, Roth M, Schinker R, Schurmann C, Scharnagl H, et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000;20:1777-83.
35. Geng Y-J, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol 1995;147:251-66.
36. Palkama T. Induction of interleukin-1 production by ligands binding to the scavenger receptor in human monocytes and the THP-1 cell line. Immunology 1991;74:432-8.
37. Palkama T, Matikainen S, Hurme M. Tyrosine kinase activity is involved in the protein kinase C induced expression of interleukin-1 beta gene in monocytic cells. FEBS Lett 1993;319:100-4.
38. Gotlieb AI, Langille BL. The role of rheology in atherosclerotic coronary artery disease. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol. 1. Philadelphia: Lippincott-Raven, 1996: 595-606.
39. Springer TA, Cybulsky MI. Traffic signals on endothelium for leukocytes in health, inflammation, and atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol. 1. Philadelphia: Lippincott-Raven, 1996:511-38.
40. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998;152:353-8.
41. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690-5.
42. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest 1994;94:885-91.
43. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci USA 1993;90:4591-5.
44. Lin MC, Almus-Jacobs F, Chen HH. Shear stress induction of the tissue factor gene. J Clin Invest 1997;99:737-44.
45. Mondy JS, Lindner V, Miyashiro JK, Berk BC, Dean RH, Geary RL. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res 1997;81:320-7.
46. McMillan DE. Blood flow and the localization of atherosclerotic plaques. Stroke 1985;16:582-7.
47. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18:842-51.
48. Hynes RO, Wagner DD. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest 1996;98:2193-5.
49. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163:1117-25.
50. Hansson GK, Libby P. The role of the lymphocyte. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol. 1. Philadelphia: Lippincott-Raven, 1996:557-68.
51. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-78.
52. Folcik VA, Aamir R, Cathcart MK. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler Thromb Vasc Biol 1997;17:1954-61.
53. Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update. Trends Immunol 2001;22:665-9.
54. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002;88:467-9.
55. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
56. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003;91:133-6.
57. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001;103:2610-6.
58. Cattaruzza M, Slodowski W, Stojakovic M, Krzesz R, Hecker M. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J Biol Chem 2003;278:37874-80.
59. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002;90:1064-71.
60. Lee YW, Kuhn H, Hennig B, Neish AS, Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001;33:83-94.
61. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995;182:33-40.
62. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-3.
63. Schönbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448-54.
64. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-9.
65. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-11.
66. Schönbeck U, Mach F, Bonnefoy J-Y, Loppnow H, Flad H-D, Libby P. Ligation of CD40 activates interleukin 1β-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1β. J Biol Chem 1997;272:19569-74.
67. Caligiuri G, Stahl D, Kaveri S, Irinopoulous T, Savoie F, Mandet C, et al. Autoreactive antibody repertoire is perturbed in atherosclerotic patients. Lab Invest 2003; 83:939-47.
68. Hansson GK. Vaccination against atherosclerosis: science or fiction? Circulation 2002;106:1599-601.
69. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 2003;167:177-85.
70. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:1547-59.
71. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003;25:79-88.
72. Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 2002;1:21-7.
73. Ludewig B, Zinkernagel RM, Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc Med 2002;12:154-9.
74. Ludewig B, Freigang S, Jaggi M, Kurrer MO, Pei YC, Vlk L, et al. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci USA 2000;97:12752-7.
75. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
76. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
77. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-9.
78. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.
79. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29:875-82.
80. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100: 2124-6.
81. van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989;61:166-70.
82. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002;23:376-83.
83. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29:292-7.
84. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:402-9.
85. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-5.
86. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001;104:3023-5.
87. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997;40:1106-14.
88. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;101:2883-8.
89. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002;46:1714-9.
90. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intimamedia detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:1489-97.
91. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002;106:981-6.
92. Danese S, Fiocchi C. Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? Circulation 2003;107:e52.
93. Vogel JD, Majors A, Sturm A. Collagen synthesis by human intestinal fibroblasts is modulated by T cells through the CD40/CD40L pathway [abstract]. Gastroenterology 2001;120:A719.
94. Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000;20:1417-20.
95. Numano F, Kishi Y, Tanaka A, Ohkawara M, Kakuta T, Kobayashi Y. Inflammation and atherosclerosis. Atherosclerotic lesions in Takayasu arteritis. Ann NY Acad Sci 2000;902:65-76.
96. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 1999;138:465-8.
97. Presti RM, Pollock JL, Dal Canto AJ, O'Guin AK, Virgin HW 4th. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998;188:577-88.
98. Weck KE, Dal Canto AJ, Gould JD, O'Guin AK, Roth KA, Saffitz JE, et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 1997;3:1346-53.
99. Hsu HY, Nicholson AC, Pomerantz KB, Kaner RJ, Hajjar DP. Altered cholesterol trafficking in herpesvirus-infected arterial cells. Evidence for viral protein kinase-mediated cholesterol accumulation. J Biol Chem 1995; 270:19630-7.
100. Nicholson AC, Hajjar DP. Herpesviruses and thrombosis: activation of coagulation on the endothelium. Clin Chim Acta 1999;286:23-9.
101. Saikku P, Leinonen M, Mattila K. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1998;2:983-6.
102. Danesh J, Whincup P, Walker M. Chlamydia pneumoniae IgG titres and coronary heart disease; prospective study and meta-analysis. Br Med J 2000;321:208-13.
103. Siscovick DS, Schwartz SM, Corey L. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The Cardiovascular Health Study. Circulation 2000;102:2335-40.
104. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. J Am Med Assoc 2003;290:1459-66.